[go: up one dir, main page]

MX2013013800A - Oligodesoxinucleotidos inmunoestimuladores. - Google Patents

Oligodesoxinucleotidos inmunoestimuladores.

Info

Publication number
MX2013013800A
MX2013013800A MX2013013800A MX2013013800A MX2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A
Authority
MX
Mexico
Prior art keywords
oligodeoxynucleotides
immunostimulatory oligodeoxynucleotides
immunostimulatory
methods
vaccines
Prior art date
Application number
MX2013013800A
Other languages
English (en)
Other versions
MX346596B (es
Inventor
Carla Christina Schrier
Thomas Simon Ilg
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2013013800A publication Critical patent/MX2013013800A/es
Publication of MX346596B publication Critical patent/MX346596B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a oligodesoxinucleótidos inmunoestimuladores, vectores y vacunas que comprenden dichos oligodesoxinucleótidos, a su uso como un medicamento, a su uso para la prevención o lucha contra enfermedades infecciosas, a métodos para la detección de dichos oligodesoxinucleótidos y a las células que se van a utilizar en estos métodos.
MX2013013800A 2011-05-26 2012-05-25 Oligodesoxinucleotidos inmunoestimuladores. MX346596B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490380P 2011-05-26 2011-05-26
EP11167602 2011-05-26
PCT/EP2012/059797 WO2012160183A1 (en) 2011-05-26 2012-05-25 Immunostimulatory oligodeoxynucleotides

Publications (2)

Publication Number Publication Date
MX2013013800A true MX2013013800A (es) 2013-12-16
MX346596B MX346596B (es) 2017-03-23

Family

ID=47216635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013800A MX346596B (es) 2011-05-26 2012-05-25 Oligodesoxinucleotidos inmunoestimuladores.

Country Status (10)

Country Link
US (1) US9359602B2 (es)
EP (1) EP2714907B1 (es)
JP (1) JP5872684B2 (es)
CN (1) CN103547674A (es)
BR (1) BR112013029968A2 (es)
CA (1) CA2834442A1 (es)
MX (1) MX346596B (es)
RU (1) RU2587633C2 (es)
WO (1) WO2012160183A1 (es)
ZA (1) ZA201308479B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012160183A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CA2914728A1 (en) 2013-06-14 2014-12-18 Intervet International B.V. Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
ES2954910T3 (es) 2014-10-03 2023-11-27 Intervet Int Bv Vacuna de amplio espectro contra el reovirus aviar
WO2016207314A2 (en) * 2015-06-26 2016-12-29 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CN105567782B (zh) * 2016-01-29 2020-08-04 山东省农业科学院畜牧兽医研究所 鸡胚成纤维细胞在体外筛选CpG寡聚脱氧核苷酸活性分子中的应用
US12239702B2 (en) 2017-12-04 2025-03-04 Intervet Inc. Vaccination with replicon particles and oil adjuvant
US11932857B2 (en) * 2017-12-15 2024-03-19 Elanco Animal Health Gmbh Immunostimulatory oligonucleotides
JP7448475B2 (ja) 2017-12-20 2024-03-12 インターベット インターナショナル ベー． フェー． 細胞関連アルファヘルペスウイルスワクチン用の改善された希釈液
JP7513614B2 (ja) 2018-12-20 2024-07-09 インターベット インターナショナル ベー． フェー． プライム－ブーストワクチン接種レジメン
CN114828882A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 多价hvt载体疫苗
EP4267179A1 (en) 2020-12-24 2023-11-01 Intervet International B.V. Multivalent hvt vector vaccine
EP4518893A1 (en) 2022-05-05 2025-03-12 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281812B2 (en) * 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
JP4516748B2 (ja) * 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
WO2004058179A2 (en) * 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
WO2007020017A1 (en) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
DE102006031483B4 (de) * 2006-07-07 2009-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Zellulärer Pyrogentest
TR201000668T1 (tr) * 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
JP5343079B2 (ja) * 2008-08-18 2013-11-13 北里第一三共ワクチン株式会社 トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法
CA2744754A1 (en) * 2008-12-09 2010-06-17 Pfizer Vaccines Llc Ige ch3 peptide vaccine
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2012160183A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides

Also Published As

Publication number Publication date
US9359602B2 (en) 2016-06-07
JP2014516533A (ja) 2014-07-17
RU2587633C2 (ru) 2016-06-20
CN103547674A (zh) 2014-01-29
EP2714907A1 (en) 2014-04-09
BR112013029968A2 (pt) 2017-01-31
JP5872684B2 (ja) 2016-03-01
ZA201308479B (en) 2014-08-27
WO2012160183A1 (en) 2012-11-29
CA2834442A1 (en) 2012-11-29
EP2714907B1 (en) 2016-06-15
MX346596B (es) 2017-03-23
US20140199345A1 (en) 2014-07-17
RU2013156635A (ru) 2015-07-10

Similar Documents

Publication Publication Date Title
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
MX2013004061A (es) Analogos de ciclosporina.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2014004862A (es) Formulaciones de polimero acrilico.
ZA201404199B (en) Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
WO2013006569A3 (en) Herpes virus vaccine and methods of use
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
MX2013004062A (es) Analogos de ciclosporina.
IN2015MN00038A (es)
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX2014015766A (es) Receptores de tipo toll y oligonucleotidos inmunoestimuladores.
ZA201404826B (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
GB2515222A (en) Use of flagellin as a vaccine
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
MX385188B (es) Vacuna de rinitis equina.
ZA201406884B (en) Modified marek's disease virus ,and vaccines made therefrom

Legal Events

Date Code Title Description
FG Grant or registration